Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, 9 November 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that the poster "A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12-month analysis of biomarkers and clinical outcomes" are now available at the Company's website.
The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis supports the data presented in June.
Title A randomised open-label phase I/II study adding ONCOS-102 to
(361): pemetrexed/cisplatin in patients with unresectable malignant
pleural mesothelioma - 12-month analysis of biomarkers and
clinical outcomes
Presenter: Prof. Luis Paz-Ares, Principal Investigator of the trial and Chair
of the Medical Oncology Department at the Hospital Doce de
Octubre, Madrid
Poster Wednesday 11. November 23:15-23:45 CET (17:15-17:45 EST)
session:
Friday 13. November 22:40-23:10 CET (16:40-17:10 EST)
Virtual Poster Hall
Location:
The poster is also available on Targovax's website (https://www.targovax.com/en/oncos-oncolytic-virus-publications-posters-and-oral-presentations/).
***
About SITC Annual Meeting 2020
The Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year to ensure the health and safety of program attendees and their patients.SITC 2020 provides a multidisciplinary educational and interactive environment focused on improving cancer patient outcomes by incorporating strategies based on basic and applied cancer immunotherapy.
***